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Abstract
Background: Viral infections such as influenza are thought to impact respiratory parameters and to promote infection
with Pseudomonas aeruginosa in patients with cystic fibrosis (CF). However, the real morbidity of the influenza virus in
CF needs to be further investigated because previous studies were only observational.
Methods: CF patients were included in a case–control study (n = 44 cases and n = 371 controls) during the 2009
pandemic A/H1N1 influenza. Cases were patients with polymerase reaction chain-confirmed influenza A/H1N1 infection.
Controls did not report any influenza symptoms during the same period. Sputum colonization and lung function were
monitored during 1 year after inclusion.
Results: Cases were significantly younger than controls (mean(SD) 14.9 years(11) versus 20.1 years (13.2) and significantly
less frequently colonized with P. aeruginosa (34 % versus 53 %). During influenza infection, 74 % of cases had pulmonary
exacerbation, 92 % had antibiotics adapted to their usual sputum colonization and 82 % were treated with oseltamivir.
Two cases required lung transplantation after A/H1N1 infection (one had not received oseltamivir and the other one had
been treated late). The cases received a mean number of antibiotic treatments significantly higher during the year after
the influenza infection (mean(SD) 2.8 (2.4) for cases versus 1.8(2.1) for controls; p = 0.002). An age-matched comparison
did not demonstrate any significant modification of bronchopulmonary bacterial colonization during the year
after influenza infection nor any significant change in FEV1 at months 1, 3 and 12 after A/H1N1 infection.
Conclusions: Our results do not demonstrate any change in sputum colonization nor significant lung disease
progression after pandemic A/H1N1 influenza.
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Background
Cystic fibrosis (CF) is characterized by a chronic ob-
structive bronchopathy with bacterial colonization and
recurrent infections which progresses towards an irre-
versible deterioration of the respiratory function and
terminal respiratory failure [1]. Chronic bronchial infection
with Pseudomonas aeruginosa was found to be a major
predictive factor of lung morbidity and patient mor-
tality [1]. The rate of pulmonary exacerbations with
this microorganism is associated with increased mor-
tality and it is important to identify pulmonary exac-
erbations that may be preventable. Viral infections,
including influenza, are clearly correlated with an in-
crease in the number of pulmonary exacerbations and
antibiotic courses, as suggested by the increase of CF
pulmonary exacerbations during the influenza season
[2–14]. Moreover, and very importantly, new bacterial
colonizations predominantly occur following viral upper
respiratory tract infections [13, 14]. This has been related
to the fact that viral infections alter host defense equilib-
rium and increase mucus production [10]. This promotes
bacterial overgrowth, and in turn, potentiates chronic
colonization because of abnormal mucociliary clearance of
CF sputum and intrinsic defect in innate immunity [14].
More specifically, the relationship between influenza virus
and P. aeruginosa infection was suggested from studies
which suggested more frequent new colonization or
increased in P. aeruginosa related exacerbation [11, 13,
15]. However, the real morbidity of the influenza virus in
CF, and its impact on new P. aeruginosa colonization,
needs to be further investigated because all previous
studies were mainly observational and did not achieve
clear-cut conclusions [4, 6, 11, 13, 15].
The 2009 pandemic A/H1N1 provided a good oppor-
tunity to study the consequences of influenza in a large
number of CF patients. Indeed, as all patients were
treated according to a consensual therapeutic protocol
based on early and systematic use of oseltamivir and
antibiotics, the variability due to different managements
was anticipated to be considerably reduced. Indeed all
patients were instructed to go immediately after onset
of symptoms to the CF center to begin oseltamivir and
antibiotic treatment as early as possible [16]. We took
advantage of this, and designed a prospective case–control
study to assess the consequences of influenza A/H1N1
infection on CF lung disease and determinate the impact




MucoFlu (Clinical Trials.gov registration number: NCT
01499914) was a prospective study initiated by INSERM
(Institut National de la Santé et de la Recherche Médicale)
and APHP (Assistance Publique des Hôpitaux de Paris) to
study A/H1N1 infection in CF patients during the 2009
pandemy. This prospective case–control study included
patients with CF followed in 14 CF centers in France and
presenting for clinics or routine hospitalizations during
the pandemic period.
Cases were CF patients with A/H1N1 infection, defined
by the association of influenza-like illness and identification
of pandemic virus A/California/7/2009 (A/H1N1v) strain
in nasal secretions using Polymerase Chain Reaction.
Influenza-like symptoms were temperature > 38 °C and
at least one of the followings: cough, sore throat, rhi-
norrhea, nasal and/or bronchial obstruction, stiffness,
asthenia, dyspnea, chest pain, or family contagion. They
were enrolled during the period of pandemics where
clinicians and patients were particularly aware for pan-
demic flu symptoms. Moreover, the patients or the parents
of the child enrolled in the Muco-Flu study all received
an information sheet about symptoms of flu and were
instructed to go immediately after onset of symptoms
to the CF centre to receive virological evaluation and
begin adequate anti-infectious treatment, based on
oseltamivir as early as possible after the onset of the
symptoms and concomitant administration of antibiotics
[16]. Enrollment of cases was as exhaustive as possible.
Sputum colonization were monitored at least at 1, 3 and
12 months after the influenza infection by collecting
sputum specimen or oropharyngeal throat swabs. All
the respiratory function tests performed during the 1 year
follow-up were collected, Transplanted patients were
excluded. Controls were defined as patients enrolled in
the MucoFlu study who did not experience any influenza-
like illness during the 2009 pandemic nor at the enroll-
ment visit. They were enrolled during routine clinics or
hospitalizations. Around one third of the whole popula-
tion followed in the CF centers (371 patients out of 1185)
was enrolled. The reason for this discrepancy is that all
the patients did not come for clinics during this period
and others refused.
Written informed consent was obtained from each pa-
tient and parents or guardians of children below 18 years
old. The protocol was conducted in accordance with the
Declaration of Helsinki and French law for biomedical
research and was approved by the Ile de France II
Ethics Committee.
Study endpoints
For each patient, case or control, demographics, mutation
in the CFTR gene, respiratory function, sputum colo-
nization and antibiotic use were recorded. For each case,
symptoms and management of influenza were collected
(treatment with oseltamivir or other neuraminidase inhibi-
tor, antibiotic treatment, hospitalization, oxygen therapy or
noninvasive ventilation initiation or modification).
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Study patients were followed from August 2009 to
January 2011. Cases were reviewed at months 1, 3 and
12 after the influenza episode. Each follow-up visit in-
cluded assessment of new bronchopulmonary colonization,
oral and intravenous antibiotic treatment history, oxygen
therapy and noninvasive ventilation, and pulmonary
function testing if available (forced expiratory volume
in one second (FEV1) and Forced Vital Capacity (FVC)).
Pulmonary exacerbation was defined according to the
Fuchs criteria [17]. Controls were followed according to
site standard of care. Three bacteriological samples during
the year of follow-up and a respiratory function test at
1 year were required as a minimum.
Bacteriological chronic colonization was defined by
identification of the same microorganism during at
least 3 months in at least 3 samplings. New bacterial
colonization was defined as the first isolation of a
microorganism or its recurrence after at least 1 year of
negative sputum culture.
Statistical analysis
Analyses were carried out with R. Data were expressed
as mean (+/-SD). The endpoints at inclusion and at dif-
ferent times of follow-up were compared in cases vs.
controls using Chi-2 or Fisher’s exact test for qualitative
variables and Wilcoxon test for continuous variables. For
further comparison of change during the year following
the pandemic in the pediatric patients, we matched 1 case
with up to 2 controls, according to age. CF-specific tables
were used in order to compare respiratory parameters of
cases versus controls and assess the percentile according
to age and sex [17]. Missing FEV1 and CVF data were
replaced by multiple imputation based on Multivariate
Imputation by Chained Equations in R. Comparisons
were made using non parametric tests, with correction
for multiple imputation. All tests were bilateral at the
0.05 significance level.
Results
Patient characteristics at inclusion
Forty-four cases of pandemic A/H1N1 influenza infection
were identified from August 2009 to February 2010 in 14
French centers. Three hundred and seventy-one CF con-
trols were included from November 2009 to February
2010 in 14 centers following 1185 patients. Those patients
were enrolled during routine clinics.
The characteristics of patients at the beginning of the
study are summarized in Table 1. There were significant
differences between cases and controls for age (14.9 years
(+/-11) for cases and 20.1 years (+/-13.2) for controls;
p = 0.01). Thirty three out of the 44 cases were below
18 years of age, including 8 patients below 6 years, 9
patients between 6 and 10 years and 16 patients between
10 and 18 years. Bronchopulmonary colonization with P.
aeruginosa was significantly less frequent among cases
(34 %) than controls (53 %). Cases had also a higher
mean FEV1 (79 % (+/-28) predicted for theoretical
value for sex and age) than the controls (65 % (+/-25).
However, as expected, considering the younger age of
the cases, this difference disappeared when FEV1 was
expressed as percentiles of CF-specific FEV1, estab-
lished in the CF population for better comparison
(52nd percentile for cases and 51th percentile for con-
trols; p = 0.78) [18]. Sixty six percent of the cases had
been vaccinated with 2009/H1N1v adjuvanted vaccine.
History of immunization was confirmed in 108 of the
371 controls. For the remaining 263 cases we do not
know whether the absence of report was due to absence
of vaccination or missing data.
Characteristics of the influenza episode
During the pandemic A/H1N1 influenza episode, all cases
had fever, 74 % experienced pulmonary exacerbation, 53 %
myalgia and 59 % asthenia. Ninety-two percent received
antibiotics (100 % of the adults and 89 % of the chil-
dren, p = 0.56), including intravenous antibiotics for
21 %,. Thirty three percent were hospitalized (27 % of
the adults and 35 % of the children, p = 0.72). Eighty-two
percent of patients were treated with oseltamivir within
Table 1 Characteristics of the cases and controls the year






Male sex, n (%) 26 (59) 186 (50) 0.26
Age, years, mean (SD) 14.9 (11.0) 20.1 (13.2) 0.01
Mutation CFTR ΔF508/ΔF508, n (%) 19 (43) 150 (40) 0.41
Bronchopulmonary bacterial colonization,
n (%)
S. aureus 34 (77) 234 (63) 0.063
P. aeruginosa 15 (34) 195 (53) 0.021
FEV1, %, mean (SD) 79 (28) 65 (25) 0.005
FVC, %, mean (SD) 87 (23) 79 (21) 0.073
Cystic fibrosis-specific FEV1,
percentiles, mean (SD)
52 (32) 51 (30) 0.78
Antibiotics, number of treatments,
mean (SD)
Oral 2.2 (1.9) 2.5 (1.9) 0.17
Intravenous 0.8 (1.5) 1.1 (1.7) 0.20
Oxygen therapy, n (%) 2 (5) 3(4) 0.86
Noninvasive ventilation, n (%) 1 (2) 1(1) 0.69
Both are compared to reference data and expressed as percent predicted
values, based on age, gender, and height
FEV1 forced expiratory volume in one second, FVC forced vital capacity,
SD standard deviation
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the first 24 h after the onset of symptoms (55 % of adults
and 90 % of children, p = 0.02).
Two adults had unfavorable outcomes after the influenza
episode versus none in controls. The first case was a
39-year woman carrying the F508del/R347L mutations
colonized with P. aeruginosa. Before the influenza epi-
sode, her FEV1 and FVC predicted were 28 and 40 %
respectively. The patient received oseltamivir 48 h after
the onset of symptoms. During the influenza episode,
she experienced hypoxemia and hypercapnia with in-
crease in oxygen therapy which led to initiation of non-
invasive ventilation 1 month later. Lung transplantation
was performed 5 months after the A/H1N1 influenza
episode because of respiratory failure.
The other case was a 33-year F508del homozygous male
patient. He was colonized with Burkholderia cepacia since
1987. His FEV1 predicted was 32 % before the influenza
episode. The patient did not receive oseltamivir due to a
delayed diagnosis. The respiratory condition of the patient
experienced a severe deterioration during the influenza
infection. Oxygen therapy was initiated during the influ-
enza episode, and noninvasive ventilation 1 month later.
Lung transplantation was performed 3 months after the
influenza episode. One month after the transplantation,
he died due to B. cepacia sepsis.
Changes in bronchial colonization and respiratory
function after the influenza episode
There was no significant change in FEV1 at months 1, 3
and 12 after the influenza episode (Table 2). Unexpectedly,
there was even a systematic trend towards an increase in
respiratory function 1 month after the viral episode. This
may reflect the proactive symptomatic and anti-infectious
treatment as indirectly suggested by the fact that cases re-
ceived a significantly higher number of antibiotic treat-
ments during the year after the influenza infection than
controls (mean of 2.8 (+/-2.4) in cases versus. 1.8 (+/-2.1)
in controls; p = 0.002). There was no difference for any
new sputum colonization including P. aeruginosa after the
influenza episode in cases compared to controls (30 %
versus. 41 %, respectively; p = 0.60).
Table 2 Characteristics of cases and controls during the year






Change in FEV1, %, mean (SD)
Month 1 12 8.3 (19.2) 198 −2.3 (8.4) 0.08
Month 3 17 0.6 (7.8) 211 −2.5 (8.7) 0.14
Month 12 28 1.2 (13.3) 249 −1.8 (11.0) 0.67
Change in FVC, %,
mean (SD)
Month 1 12 7.4 (18.1) 198 −3.9 (8.8) 0.05
Month 3 17 0.7 (8.7) 212 −2.5 (8.9) 0.16
Month 12 28 1.9 (12.7) 252 −2.6 (9.8) 0.10
Antibiotics, number of treatments,
mean (SD)
Oral 44 2.8 (2.4) 371 1.8 (2.1) 0.002
Intravenous 44 0.6 (1.3) 371 0.8 (1.54) 0.42
New bronchopulmonary colonization,
n (%)
Any germ 44 13 (30) 371 151 (41) 0.60
H. influenza 44 1 (2) 371 32 (8) 0.13
S. aureus 44 3 (7) 371 39 (11) 0.42
P. aeruginosa 44 6 (14) 371 36 (10) 0.48
B. cepacia 44 0 371 5 (1) 0.42
A. fumigatus 44 3 (7) 371 39 (11) 0.42
Oxygen therapy, n (%) 44 2 (5) 371 30 (8) 0.41
Noninvasive ventilation, n (%) 44 2 (5) 371 12 (3) 0.65
Both are compared to reference data and expressed as percent predicted
values, based on age, gender, and height
FEV1 forced expiratory volume in one second, FVC forced vital capacity,
SD standard deviation
Table 3 Characteristics of the cases during the year after A/H1N1
2009 pandemic influenza according to age
n Cases <18 years
(n = 33)





Month 1 33 8.8 (18.0) 11 4.5 (16.92) 0.66
Month 3 33 0.8 (8.3) 6 0.5 (5.2) 0.97
Month 12 33 −1.5 (11.0) 9 3.9 (13.6) 0.26
Change in FVC,
%, mean (SD)a
Month 1 33 5.4 (15.3) 11 4.3 (12.2) 0.88
Month 3 33 0.9 (8.1) 11 −0.8 (5.4) 0.60
Month 12 33 −0.6 (10.9) 11 6.4 (13.9) 0.11
Antibiotics, number of treatments,
mean (SD)
Oral 33 2.7 (2.2) 11 3.3 (2.8) 0.57
Intravenous 33 0.5 (1.1) 11 0.9 (1.6) 0.34
New bronchopulmonary germ colonization,
n (%)
Any germ 33 13 (39) 11 0 0.013
H. Influenza 33 1 (3) 11 0 0.54
S. Aureus 33 3 (9) 11 0 0.29
P. Aeruginosa 33 6 (18) 11 0 0.12
B. Cepacia 33 0 (0) 11 0 1.00
A. Fumigatus 33 3 (9) 11 0 0.32
Both are compared to reference data and expressed as percent predicted
values, based on age, gender, and height
FEV1 forced expiratory volume in one second, FVC forced vital capacity,
SD standard deviation
aMissing data were imputed
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As expected, the pediatric (<18 years) versus the adult
cases did not differ significantly neither for FEV1, FVC
changes or the number of antibiotic courses during the
year after the influenza episode (Table 3). Because of
many missing data for FEV1 and FVC, comparison were
made using non parametric tests, with correction for
multiple imputation. Average of data after imputation
were very similar to those of observed data, with, as ex-
pected, larger standard deviations (data not shown).
As a whole, children infected with A/H1N1 influenza
experienced significantly more frequently a new broncho-
pulmonary bacterial colonization in comparison to adults
(39 % versus 0 %; p = 0.013), although the level of signifi-
cance was not reached for any microorganism (P. aerugi-
nosa, Staphylococcus aureus, Haemophilus influenzae, B.
cepacia and Aspergillus fumigatus). Interestingly however,
the largest difference in incidence was for P. aeruginosa
(6 new colonizations in the pediatric population versus
none in the adults, p = 0.12).
As controls were very different from cases for several
parameters as age, bacterial colonization and respiratory
function, we compared pediatric cases and age–matched
controls in order to detect whether the increased incidence
in P. aeruginosa new colonization was related to the influ-
enza infection or simply to the difference in age (Table 4).
Age and FEV1 were similar at baseline in this matched
subset. The increase for new P. aeruginosa colonization
among the patients who experienced influenza infection
versus the controls disappeared. The overall incidence of
new colonization was even somewhat larger in controls,
especially due to more new colonizations with H. influen-
zae in the controls in comparison with cases (16 % versus
3 %; p = 0.04). Controls displayed a trend to more oral anti-
biotic courses than controls during the year of follow-up.
Discussion
This study is the first to prospectively assess the impact
of an influenza episode and of a proactive anti-infectious
strategy in a large case–control cohort of patients with
CF. Results clearly show that pandemic A/H1N1 influenza
did not lead to significant increase in new colonization
nor changes in respiratory function during the year after
the influenza episode. Early antiviral therapy seems crucial
to limit deleterious consequences of A/H1N1 disease in
CF patients.
Mitigation of potential study bias
We deliberately chose to evaluate only the patients with
virologically proven influenza infection. As we did not
perform influenza serology in the controls enrolled in
the study, we do not know if any of the controls may
have contracted asymptomatic H1N1 before the start of
recruitment and during the study period. To minimize
this bias, the controls were patients who never experi-
enced any symptoms of influenza infection during the
pandemic period.
Clearly, controls are very different from cases for age,
history and clinical parameters, which precludes to draw
firm conclusions from the comparison of the 2 popula-
tions. To address this main drawback, we first checked
from the french CF 2010 registry that the controls are
representative of the general CF population. We then
performed age-matched comparison in the pediatric
patients, one case matched with up to 2 controls ac-
cording to age. Age, FEV1 and bacteriological pattern
of colonization were similar at baseline, demonstrating
the comparability of this matched subset. Two different
reasons may explain the majority of children among the
infected cases. The first one is that the 2009 influenza A
(H1N1) pandemic predominantly affected young age
groups [19]. In France, according to the French influenza
network, the less than 15 years of age were the most fre-
quently infected, mainly the 5–9 years, as assessed from
out-patients visits for Influenza like Illness [20]. The
second one may be related to the increased awareness
for clinical symptoms of the parents of CF children and
the pediatrician, based on reports of severe outcomes
in children [19].
A large proportion of lung function data are missing.
This is because on the one hand, clinicians provided data
according to local follow-up, and on the other hand,
young children did not perform reliable respiratory func-
tions. To handle missing data and minimize this problem,
Table 4 New broncho-pulmonary colonization and antibiotic
courses of pediatric cases and age-matched controls during the






Age 33 9.7+/- 4.7 55 9.5+/- 4.8 0,9
Antibiotics, number of treatments, mean (SD)
Oral 33 2.7 (2.2) 55 2.4 (2.6) 0.40
Intravenous 33 0.52 (1.12) 55 0.56 (2.01) 0.33
New bronchopulmonary colonization, n (%)
Any germ 33 13 (39) 55 26 (47) 0.47
H. influenza 33 1 (3) 55 9 (16) 0.04
S. aureus 33 3 (9) 55 6 (11) 0.78
P. aeruginosa 33 6 (18) 55 6 (11) 0.44
B. cepacia 33 0 55 1 (2) 0.40
A. fumigatus 33 3 (9) 55 4 (7) 0.94
Oxygen therapy, n (%) 33 0 (0) 55 0 (0) 1
Noninvasive ventilation, n (%) 33 0 (0) 55 0 (0) 1
Both are compared to reference data and expressed as percent predicted
values, based on age, gender, and height
FEV1 forced expiratory volume in one second, FVC forced vital capacity,
SD standard deviation
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we used multiple imputation model and checked that the
average of data after imputation were very similar to those
of observed data, Nevertheless, as a substantial proportion
of lung function data is missing at 1 month, it is impos-
sible to draw any meaningful conclusions on the short
term effect of influenza infection. Mid -term effects of an
influenza episode can be better estimated, as 2/3 of pa-
tients contributed data.
Two third of the cases were vaccinated with 2009/
H1N1v adjuvanted vaccine but nevertheless underwent
influenza infection. This is in line with our previous
study, where we demonstrated that patients with CF
seroconverted less than the general population [21]. As
we miss information about pandemic H1N1 immunization
in 2/3 of the controls, it is impossible to draw any firm
conclusion about the influence of pandemic (H1N1) vac-
cination in our cohort.
Benign short term evolution of A/H1N1 influenza
infection
Although 75 % of patients experienced pulmonary ex-
acerbation during the pandemic A/H1N1 influenza epi-
sode, the majority of patients had a benign evolution
after infection with A/H1N1 influenza. This result may
be partly related to the fact that 75 % of cases were chil-
dren with moderate disease. Two patients out of 44 had
severe decompensation of their respiratory disease, leading
to lung transplantation in the months after the influenza
episode. Those patients were the most severe of the sample
(respective FEV1 predicted at 28 and 32 %, versus 82 %
(36–138 %) for the 42 remaining others). Infection with B.
cepacia in one of the 2 patients is possibly a risk factor of
worse evolution after A/H1N1 infection as suggested by
the fact that 8 controls also infected with B. cepacia did
not have any modification of their respiratory function
during the study period.
Those observations are in line with previous studies of
A/H1N1 influenza which showed that the majority of
patients were below 18 years of age and had a benign
short term evolution both in CF [22–25] and outside CF
[26–28]. Respiratory worsening including mechanical
ventilation and premature death has been reported only
in a small number of patients, mainly in adults with se-
vere CF lung disease [15, 22]. In the retrospective study
of Viviani et al [15], H1N1 infection had a significant
impact on the disease course in patients with CF (110
patients diagnosed with A/H1N1 infection): 53 % re-
quired intravenous antibiotic therapy, 48 % were hospi-
talized for an average of 12.9 days and 31 % required
oxygen treatment during the time of infection. Six pa-
tients, all with severe lung disease required intensive
care unit, 5 of them needing mechanical ventilation and
3 died during the course of the infection. Although the
authors state that, as a whole, FEV1 did not change after
A/H1N1 infection, this parameter was significantly lower
in hospitalized patients. However the absence of case
control design in both of these studies does not allow
any formal conclusion [15, 22].
Maximal early treatment is mandatory after A/H1N1
infection
Systematic early prophylactic treatment with oseltamivir
within 48 h was recommended in CF patients by French
Health Authorities in case of influenza-like symptoms in
this pandemic context, taking into account the potential
bad prognosis. In our study, 82 % of the cases were
treated with oseltamivir, 92 % with antibiotics and one
third were hospitalized. Although not achieving statistical
significance, a transient improvement of the respiratory
function was observed at month 1, most probably due to
this increased proactive treatment. This could also explain
why the proportion of new colonization with H. influenza
in patients < 18 years was higher in controls compared to
cases as this bacteria may have been eradicated by anti-
biotic treatment prescribed during the flu episode.
Very importantly, in the two most severe cases, oselta-
mivir was either not administered or the delay of admin-
istration was more than 48 h after the beginning of the
episode. On the opposite, all other benign cases received
oseltamivir within 24 h after the beginning of the symp-
toms. A recent study also showed that early treatment
with oseltamivir in hospitalized children decreased the
clinical severity of A/H1N1 influenza [29]. Conversely,
late treatment with oseltamivir treatment (>48 h after
onset of symptoms) was shown to be associated with
more severe exacerbations [23]. We point out however,
that the absence of randomized controlled data in our
study does not allow to draw any firm conclusion about
specific benefit of neuraminidase inhibitors in CF.
Nevertheless, our results suggest that early management
and follow-up is crucial to limit deleterious conse-
quences of A/H1N1 disease in CF patients.
Case–control study shows a limited impact on lung
disease in the year after A/H1N1influenza infection
During the year following A/H1N1 infection, there was
no significant increase in oxygen therapy and noninvasive
ventilation. We did not observe any significant changes in
functional respiratory parameters (FEV1, FVC). These
results are in line with other reports that also did not evi-
dence any decrease of respiratory functions after A/H1N1
infection [15, 22, 24]. This may be related to a more close
follow-up and increased proactive treatment as suggested
by the fact that cases received a mean number of anti-
biotic treatments significantly higher during the year after
the influenza infection in 2009 (mean of 2.8 +/- 2.4 in
cases versus 1.8 +/- 2.1 in controls; p = 0.002). Interest-
ingly, antibiotic courses were not prescribed in the months
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following the influenza wave but rather all throughout the
year. Although this increased “vigilance” is only a specula-
tion, it must be underlined that the CF medical commu-
nity was very concerned by the potential bad prognosis
after A/H1N1 infection [19].
Chronic colonization with P. aeruginosa is one of the
main prognosis factor in CF. In patients with CF, the
increase in the number of P. aeruginosa colonization
during winter has been strongly correlated with seasonal
influenza [11], therefore suggesting that previous infec-
tion with influenza made the lung mucosa prone to
bacterial colonization. Indeed, influenza viral infection
can alter host defense equilibrium, by destruction and
desquamation of the mucous membrane, increase in air-
way resistance and mucus production. This impedes
clearance of inhaled microorganisms, hence promoting
colonizing bacterial overgrowth and consecutive bacterial
infections [30, 31]. This may on the one hand lead to the
development of chronic P. aeruginosa infection in lungs
hitherto uncolonised, or only intermittently colonised, and
even initiate signs of chronic respiratory disease in chil-
dren with CF. This is suggested in a prospective observa-
tional study, where 11 % of the cases initially free of P.
aeruginosa, became colonized after A/H1N1 influenza in-
fection [15]. On the other hand, virus may promote over-
growth, dispersion and invasion of chronic mucoid P.
aeuginosa embedded in biofilm [32]. This is suggested by
2 observational studies showing a more frequent pulmon-
ary deterioration following non-bacterial infection when
chronic bacterial infection is present [33] and the increase
in precipitins to P. aeruginosa coincidental with the viral
infection [4].
We did not find such a difference in our study: 14 %
of cases underwent a new P. aeruginosa colonization,
but also 10 % of controls. Very importantly, the case–
control design allowed correcting a possible bias related
to age-dependant colonization. Indeed, the comparison
of the pediatric cases versus the adult ones showed that
patients below 18 years significantly underwent more
new bacterial colonization during the year after influ-
enza infection (39 %, for pediatric cases versus none for
adults, p = 0.013) with a specific increase in P. Aeruginosa
(6 pediatric cases versus none among the adults) (Table 3).
After matching pediatric cases with controls according to
age, this initial difference disappeared (Table 4). Similarly,
a study in adults with CF did not find any change in spu-
tum culture growth in the overall group before and after
A/H1N1 infection [24]. This difference obtained by com-
paring pediatric with adult cases probably simply reflected
the fact that children experienced more frequently new
bacterial colonization because they were not yet colonized
in contrast to adults. This also underscores the necessity
of case–control studies for rigorous interpretation of data
and avoiding potential bias of interpretation.
Conclusion
The pandemic influenza A/H1N1 virus has now adopted
the properties of a seasonal influenza virus in the post-
pandemic period [34]. Therefore, our observations not
only concern the specific pandemics of A/H1N1, but may
be generalized to epidemics of seasonal A/H1N1 flu.
Our results suggest that a proactive antiviral and anti-
bacterial early treatment may limit the impact of A/H1N1
in CF patients, quite particularly sputum colonization and
lung disease progression. More generally, this underscores
the need to treat early CF patients with respiratory viral
infections and to prevent respiratory exacerbation with
antibiotics.
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